The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

Chemistry World welcomes letters, which should be concise (normally fewer than 300 words) and timely. Those selected for ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test ...

The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in ...

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

A' by itself is also possibly Latin, but 'stra' by itself is nonsense." She added, "'zeneca', whether separated into two words or not, has no meaning or roots in Latin." Mikael Papadimitriou ...

Investing.com -- AstraZeneca (NASDAQ:AZN) has announced significant results from its BATURA Phase III trial. The trial has shown that Airsupra, AstraZeneca’s anti-inflammatory reliever rescue ...